RLAY Reports 60% Volumetric Response Rate, 89% Clinical Improvement in Zovegalisib Trial for Vascular Anomalies, Expansion Cohorts Opened
Relay Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $14.26
+16% in 7d after detection
Post-detection moves
1h
—
1d
+7.9%
3d
+12%
7d
+16%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS